HTA

Market Access

Beyond the Bill: how do we make medicines affordable without...

Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.

Market Access

Early strategic evidence planning is a key success factor in...

As the European Union (EU) ushers in a new era of health technology regulation, pharmaceutical companies face both unprecedented challenges and opportunities.

Market Access

One in five expressions of interest in UK regulator's pilot ...

The MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence scientific dialogue programme.

Market Access

Is money the only metric that really matters in UK’s VPAG? I...

The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.

Digital

Health Technology Assessment – Challenges and opportunities ...

Changes to Health Technology Assessment in Europe offer new opportunities to streamline processes and get innovative treatments to market faster

Market Access

Managing the challenges and embracing the opportunities of E...

The way HTAs are conducted in Europe is changing. And, if organisations act now to overcome the challenges, they could reap the rewards for years to come.

Beyond the Bill: how do we make medicines affordable without...

Early strategic evidence planning is a key success factor in...

One in five expressions of interest in UK regulator's pilot ...

Is money the only metric that really matters in UK’s VPAG? I...

Health Technology Assessment – Challenges and opportunities ...

Managing the challenges and embracing the opportunities of E...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

HTA

Editor's Picks